Modality
Gene Editing
MOA
PARPi
Target
B7-H3
Pathway
Epigenetic
LGS
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Jul 2026
Phase 1Current
NCT06446459
2,901 pts·LGS
2017-05→2026-07·Not yet recruiting
NCT04988959
2,887 pts·LGS
2025-08→TBD·Completed
5,788 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-083mo awayInterim· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Not yet…
P1
Complet…
Catalysts
Interim
2026-07-08 · 3mo away
LGS
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06446459 | Phase 1 | LGS | Not yet recr... | 2901 | NT-proBNP |
| NCT04988959 | Phase 1 | LGS | Completed | 2887 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 |